Physicians' Academy for Cardiovascular Education

Role of a non-steroidal MRA in the treatment spectrum of patients with T2DM and CKD

Click here for the CME course on ReachMD
10' education - Feb. 8, 2022 - Prof. Peter Rossing, MD (Copenhagen, Denmark), prof. Gerasimos Filippatos, MD (Athens, Greece) and prof. Matthew Weir, MD (Baltimore, MD, USA)

Video navigation menu

  • Unmet need for patients with CKD and T2DM 01:34
  • The FIDELIO-DKD and FIGARO-DKD clinical trials 03:30
  • How do we identify patients for treatment with finerenone? 06:00
  • FIndings from recent analyses of trials with finerenone 08:33
  • Take-home messages 12:28

Educational information

This video was distributed by our partner, ReachMD, a leading online learning platform for physicians and other healthcare professionals.

Faculty

Disclosures

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PACE-cme.

Funding

Funding for this educational program was provided by and independent educational grant from Bayer AG.

Click here for the CME course on ReachMD

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: